Defining "adequate" pathogen reduction performance for transfused blood components.
about
Component pathogen inactivation: a critical review.UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma.Human Immunodeficiency Virus (HIV).Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.Update on the use of pathogen-reduced human plasma and platelet concentrates.Safety of the blood supply.Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for BacteriaInactivation of model viruses and bacteria in human fresh frozen plasma using riboflavin and long wave ultraviolet rays.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment.Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma.Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.Development of a riboflavin and ultraviolet light-based device to treat whole blood.Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety.
P2860
Q34310415-E09252E9-C33A-4471-8825-284B8A16B84BQ35095651-221644F9-5C6B-4C54-9FAB-D27D8A2EB539Q37045832-1F1A47D2-9354-46F5-9DD7-6C06F0B7407DQ37903671-9C696A26-B3AB-40EF-B927-BD10E88F41A7Q38109665-8EE69EDF-3474-4955-9146-15530D2CCE2BQ38287590-D11B7C37-0EE9-402B-A686-81131864E2A6Q38667338-22C0E22C-A5C1-4BAC-9620-BFC0F2AA3069Q40095226-DBB31277-62B3-414F-A3E4-EED534E67233Q40942917-1A3D5BE1-1195-4AB9-91CE-4948645CEC6CQ42158238-5D4977EE-14B0-4728-90B2-8A62BD385D02Q42220047-8371D8A9-4987-4F38-9C75-425B6B4CC0C9Q42258338-DDBF54C0-18ED-4FDD-AE58-2AC8D09170F3Q42278634-86F40FFB-45CC-4753-ADFB-6477BFF92AFBQ43146818-B6E63521-6333-4A18-A79C-7DBC4882BB5DQ44120840-3BCB3425-3D2B-46D5-83FA-FDF1E8CE2B49
P2860
Defining "adequate" pathogen reduction performance for transfused blood components.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Defining "adequate" pathogen reduction performance for transfused blood components.
@ast
Defining "adequate" pathogen reduction performance for transfused blood components.
@en
Defining "adequate" pathogen reduction performance for transfused blood components.
@nl
type
label
Defining "adequate" pathogen reduction performance for transfused blood components.
@ast
Defining "adequate" pathogen reduction performance for transfused blood components.
@en
Defining "adequate" pathogen reduction performance for transfused blood components.
@nl
prefLabel
Defining "adequate" pathogen reduction performance for transfused blood components.
@ast
Defining "adequate" pathogen reduction performance for transfused blood components.
@en
Defining "adequate" pathogen reduction performance for transfused blood components.
@nl
P2093
P2860
P1433
P1476
Defining "adequate" pathogen reduction performance for transfused blood components.
@en
P2093
Brian Custer
Raymond P Goodrich
Shawn Keil
P2860
P304
P356
10.1111/J.1537-2995.2010.02635.X
P577
2010-08-01T00:00:00Z